| Literature DB >> 34285546 |
Meilong Wu1,2, Shizhong Yang1,2, Xiaobin Feng1,2, Chengquan Li1,2, Xiangchen Liu1,2, Zhenyu Zhang1,2, Ying Xiao1,3, Chuchu Liu4, Jiahong Dong1,2.
Abstract
PURPOSE: Previous studies have shown that various preoperative inflammatory indicators can predict the prognosis of hepatocellular carcinoma (HCC), but the role of postoperative inflammatory indicators remains unclear. This study aimed to explore the prognostic value of postoperative inflammatory indicators and whether combining preoperative and postoperative inflammatory indicators can improve the predictive performance of the prognostic model. PATIENTS AND METHODS: Eighty-eight patients with primary HCC were included in this study. A preoperative model, postoperative model, and combined model that integrated preoperative and postoperative inflammatory indicators were established. The prognostic value of the models was evaluated by the area under the curve of time-dependent receiver operating characteristic curves (td-AUC).Entities:
Keywords: disease-free survival; hepatocellular carcinoma; inflammation; neutrophil-lymphocyte ratio; postoperative
Year: 2021 PMID: 34285546 PMCID: PMC8286132 DOI: 10.2147/JIR.S316177
Source DB: PubMed Journal: J Inflamm Res ISSN: 1178-7031
Figure 1Selection of patients included in the analysis.
Clinicopathological Features of HCC Patients
| Variable | Cohort (n=88) |
|---|---|
| Gender (male) | 62 (70.50%) |
| Age (>60 year) | 37 (42%) |
| HBsAg (positive) | 68 (77.3%) |
| Tumor size (>5 cm) | 40 (45.5%) |
| BCLC stage | |
| 0 | 12 (13.6%) |
| A | 60 (68.2%) |
| B | 7 (8.0%) |
| C | 9 (10.2%) |
| Tumor number (Multiple) | 16 (18.2%) |
| Tumor differentiation (poor) | 11 (12.5%) |
| MVI (present) | 28 (31.8%) |
| Liver cirrhosis (present) | 37 (42.0%) |
| Tumor necrosis (yes) | 40 (45.5%) |
| Satellite nodules (present) | 7 (8.0%) |
| Capsule invasion (present) | 53 (60.2%) |
| AFP (>20 ng/mL) | 64 (72.7%) |
| PreNLR* | 1.84 (0.65–8.66) |
| PredNLR* | 1.40 (−0.17–2.27) |
| PrePLR* | 101.03 (29.05–666.67) |
| PrePNI* | 48.13 (36.45–64.10) |
| PreLMR* | 3.34 (0.94–8.35) |
| PostNLR* | 3.06 (0.83–14.81) |
| PostdNLR* | 1.63 (1.22–3.31) |
| PostPLR* | 127.14 (31.19–642.86) |
| PostPNI* | 42.30 (7.76–60.85) |
| PostLMR* | 2.14 (0.80–5.34) |
Note: *Data are presented as medians (range).
Abbreviations: AFP, alpha-fetoprotein; BCLC, Barcelona Clinic Liver Cancer stage; HBsAg, hepatitis B surface antigen; MVI, microvascular invasion; prePLR, preoperative platelet-lymphocyte ratio; preLMR, preoperative lymphocyte-monocyte ratio; prePNI, preoperative prognostic nutritional index; preNLR, preoperative neutrophil-lymphocyte ratio; predNLR, preoperative derived neutrophil-lymphocyte ratio; postPLR, postoperative platelet-lymphocyte ratio; postLMR, postoperative lymphocyte-monocyte ratio; postPNI, postoperative prognostic nutritional index; postNLR, postoperative neutrophil-lymphocyte ratio; postdNLR, postoperative derived neutrophil-lymphocyte ratio.
Optimal Cutoff Values for Preoperative and Postoperative Inflammation Indicators
| Variable | High | Low |
|---|---|---|
| PreNLR | >3.22 (12.5%) | ≤ 3.22 (87.5%) |
| PredNLR | >1.29 (79.5%) | ≤1.29 (20.5%) |
| PrePLR | >61.07 (88.6%) | ≤61.07 (11.4%) |
| PrePNI | >44.35 (58.0%) | ≤44.35 (22.7%) |
| PreLMR | >2.16 (90.9%) | ≤2.16 (9.1%) |
| PostNLR | >3.25 (43.2%) | ≤3.25 (56.8%) |
| PostdNLR | >1.44 (88.6%) | ≤1.44 (11.4%) |
| PostPLR | >91.53 (71.6%) | ≤91.53 (28.4%) |
| PostPNI | >41.75 (58.0%) | ≤41.75 (42%) |
| PostLMR | >2.48 (23.9%) | ≤2.48 (76.1%) |
Abbreviations: prePLR, preoperative platelet-lymphocyte ratio; preLMR, preoperative lymphocyte-monocyte ratio; prePNI, preoperative prognostic nutritional index; preNLR, preoperative neutrophil-lymphocyte ratio; predNLR, preoperative derived neutrophil-lymphocyte ratio; postPLR, postoperative platelet-lymphocyte ratio; postLMR, postoperative lymphocyte-monocyte ratio; postPNI, postoperative prognostic nutritional index; postNLR, postoperative neutrophil-lymphocyte ratio; postdNLR, postoperative derived neutrophil-lymphocyte ratio.
Figure 2Kaplan‑Meier survival curves of DFS based on preoperative inflammatory indicators. (A) preNLR, (B) predNLR, (C) preLMR, (D) prePLR, (E) prePNI.
Figure 3Kaplan‑Meier survival curves of DFS based on postoperative inflammation indicators. (A) postNLR, (B) postdNLR, (C) postLMR, (D) postPLR, (E) postPNI.
Univariate and Multivariate Analysis of DFS
| Variable | Univariate | Multivariate (Combined Model) | ||
|---|---|---|---|---|
| HR (95% CI) | P | HR (95CI%) | P | |
| Gender (male) | 1.437 (0.748–2.758) | 0.276 | ||
| Age (>60 year) | 0.902 (0.510–1.595) | 0.722 | ||
| HBsAg (positive) | 1.604 (0.749–3.434) | 0.224 | ||
| Tumor size (>5 cm) | 1.550 (0.884–2.719) | 0.126 | ||
| Tumor number (Multiple) | 2.227 (1.149–4.318) | 0.018 | 3.378 (1.603–7.117) | 0.001 |
| Tumor differentiation (poor) | 1.757 (0.851–3.629) | 0.128 | ||
| MVI (present) | 1.830 (1.020–3.281) | 0.043 | ||
| Liver cirrhosis (present) | 1.105 (0.628–1.945) | 0.729 | ||
| Tumor necrosis (yes) | 1.314 (0.747–2.309) | 0.343 | ||
| Satellite nodules (present) | 2.518 (1.063–5.966) | 0.036 | ||
| Capsule invasion (present) | 1.247 (0.697–2.230) | 0.457 | ||
| AFP (>20 ng/mL) | 2.188 (1.059–4.517) | 0.034 | 3.340 (1.561–5.576) | 0.002 |
| PreNLR (high) | 2.590 (1.244–5.392) | 0.011 | ||
| PredNLR (high) | 2.832 (1.122–7.153) | 0.028 | ||
| PrePLR (low) | 0.455 (0.211–0.977) | 0.043 | 0.231 (0.099–0.538) | 0.001 |
| PrePNI (low) | 0.412 (0.226–0.754) | 0.004 | 0.281 (0.143–0.554) | <0.001 |
| PreLMR (low) | 0.422 (0.188–0.948) | 0.037 | ||
| PostNLR (high) | 2.403 (1.360–4.248) | 0.003 | 3.580 (1.906–6.725) | <0.001 |
| PostdNLR (high) | 8.562 (1.181–62.087) | 0.034 | ||
| PostPLR (low) | 0.720 (0.396–1.310) | 0.282 | ||
| PostPNI (low) | 0.457 (0.256–0.815) | 0.008 | ||
| PostLMR (low) | 0.260 (0.103–0.657) | 0.004 | ||
Abbreviations: AFP, alpha-fetoprotein; CI, confidence interval; HR, hazard ratio; HBsAg, hepatitis B surface antigen; MVI, microvascular invasion; prePLR, preoperative platelet-lymphocyte ratio; preLMR, preoperative lymphocyte-monocyte ratio; prePNI, preoperative prognostic nutritional index; preNLR, preoperative neutrophil-lymphocyte ratio; predNLR, preoperative derived neutrophil-lymphocyte ratio; postPLR, postoperative platelet-lymphocyte ratio; postLMR, postoperative lymphocyte-monocyte ratio; postPNI, postoperative prognostic nutritional index; postNLR, postoperative neutrophil-lymphocyte ratio; postdNLR, postoperative derived neutrophil-lymphocyte ratio.
Multivariate Analysis of Preoperative and Postoperative Models
| Variable | Preoperative Model | Postoperative Model | ||
|---|---|---|---|---|
| HR (95% CI) | P | HR (95CI%) | P | |
| Tumor number (multiple) | 2.731 (1.303–5.727) | 0.008 | 2.336 (1.156–4.721) | 0.018 |
| Satellite nodules (present) | 2.565 (1.051–6.259) | 0.038 | ||
| AFP (>20 ng/mL) | 2.294 (1.020–5.160) | 0.045 | 2.229 (1.036–4.798) | 0.040 |
| PrePLR (low) | 0.236 (0.101–0.553) | 0.001 | ||
| PrePNI (low) | 0.338 (0.168–0.682) | 0.002 | ||
| PreLMR (low) | 0.331 (0.132–0.825) | 0.018 | ||
| PostNLR (high) | 3.189 (1.736–5.860) | <0.001 | ||
Abbreviations: AFP, alpha-fetoprotein; CI, confidence interval; HR, hazard ratio; prePLR, preoperative platelet-lymphocyte ratio; prePNI, preoperative prognostic nutritional index; preLMR, preoperative lymphocyte-monocyte ratio; postNLR, postoperative neutrophil-lymphocyte ratio.
Figure 4Nomogram of the preoperative model.
Figure 5Calibration curve of the preoperative model for (A) 2 years and (B) 3 years.
Figure 6Nomogram of the postoperative model.
Figure 7Calibration curve of the postoperative model for (A) 2 years and (B) 3 years.
Figure 8Nomogram of the combined model.
Figure 9Calibration curve of the combined model for (A) 2 years and (B) 3 years.
Figure 10Different independent prognostic factors of the combined model and the area under the time-dependent ROC for predicting (A) 2-year and (B) 3-year DFS.
Figure 11Different models and the area under the time-dependent ROC for predicting (A) 2-year and (B) 3-year DFS.